US Bancorp’s Jasper Therapeutics JSPR Stock Holding History

US Bancorp’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$438	Hold	500	–	–	﹤0.01%	4016
2025 Q4	$915	Hold	500	–	–	﹤0.01%	3868
2025 Q3	$1.19K	Hold	500	–	–	﹤0.01%	3816
2025 Q2	$2.77K	Hold	500	–	–	﹤0.01%	3800
2025 Q1	$2.15K	Sell	500 -11	-2%	-$73	﹤0.01%	3863
2024 Q4	$10.9K	Sell	511 -1	-0.2%	-$21	﹤0.01%	3377
2024 Q3	$9.63K	Buy	+512	New	+$10.2K	﹤0.01%	3379

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

US Bancorp's JSPR Position: Q1 2026 in Review

US Bancorp held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 500 shares worth $438. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

US Bancorp first reported a position in JSPR in Q3 2024 and has held it in 7 quarters since. The position peaked at $10.9K in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

US Bancorp held 500 shares of Jasper Therapeutics worth $438 as of Q1 2026.
US Bancorp left its Jasper Therapeutics share count unchanged in Q1 2026.
Jasper Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4016 holding.
US Bancorp first reported a position in Jasper Therapeutics in Q3 2024 and has held it in 7 quarters since.
US Bancorp's Jasper Therapeutics position peaked at $10.9K in Q4 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.